source
- Roche expands obesity R&D footprint with Rona deal worth $1B+Roche has gained access to a genetic obesity approach from China's Rona Therapeutics for up to $100 million in upfront and near-term payments.
- J&J’s innovative medicines carried Q3 as medtech disappoints, but newer medicines absentWhile innovative medicine supported Johnson & Johnson’s “in line” earnings for the third quarter of 2026, investors were disappointed to see older medicines carrying the bag.